Clinical experience with different pegylated interferons: Is there a difference?

Abstract

The acute phase of hepatitis C virus (HCV) infection represents a key point in the evolution of hepatitis C. The infection either resolves spontaneously, or progresses into chronic disease. However, the asymptomatic nature of acute hepatitis C contributes to difficulties in detection, diagnosis and hence, the assessment of therapy when indicated. Controversies in chronic HCV related to the implications of both selected predictors of treatment outcome and clinical experience with structurally different Peg-IFNs are discussed.